Will your doctor give you Mounjaro for weight loss?

The decision your doctor is actually weighing up

It is entirely reasonable to wonder whether your doctor will simply say no. Lots of people sitting in that position feel a mixture of hope and anxiety, they know the evidence is strong, they have read the headlines, and they are not sure whether their circumstances tick the right boxes. The honest answer is that the decision rests on a clinical framework, not a doctor's personal view of weight loss.

Tirzepatide carries a UK licence for adults with a BMI of at least 30, or at least 27 where a weight-related condition is already present. That condition could be prediabetes, hypertension, raised cholesterol, obstructive sleep apnoea or cardiovascular disease, among others. For some ethnic backgrounds (South Asian, Chinese, Middle Eastern, Black African or African-Caribbean) UK guidance applies thresholds that are 2.5 kg/m² lower. So the first question your doctor asks is simply: does this person meet the licensed criteria? If the answer is yes, the clinical case for prescribing exists. More detail on the tirzepatide clinical profile is available if you want the pharmacology alongside the eligibility picture.

Your doctor will also screen for contraindications: a personal or family history of certain thyroid tumours or a condition called MEN2, a history of pancreatitis, and some gastrointestinal conditions may make Mounjaro unsuitable. Pregnancy, breastfeeding and a plan to conceive in the near future are reasons it would not be prescribed. These are not arbitrary barriers, they reflect the medicine's known profile and what the NHS's guidance on tirzepatide sets out for patients.

What your NHS GP can (and currently cannot) do

This is where many people get confused. NHS GPs gained the ability to prescribe tirzepatide for weight management through the new 2026/27 GP contract, but the rollout is phased and practice-level participation is optional. In the first phase (from June 2025), NHS access is limited to adults with a BMI of 40 or above who also have four or more specific weight-related conditions from a defined list. The BMI threshold widens in subsequent phases, with adults who have a BMI of 35 to 39.9 and four or more of those conditions becoming eligible from around June 2026. Even then, every NHS patient is required to take part in a wraparound diet and activity programme, meeting the numerical criteria does not by itself trigger a prescription.

If you sit below those NHS thresholds, your GP is not in a position to prescribe on NHS terms right now, regardless of how sympathetic they are. That is the practical reality the phased rollout creates, and it is why many people who are clinically eligible under the medicine's licence find themselves turning to a private route instead. A private Mounjaro prescription from a doctor operates on the licence criteria rather than the narrower NHS commissioning rules.

The distinction matters because private prescribers assess against the licensed indications, the ones the MHRA approved when it authorised the medicine. Those are broader than the current NHS access phases. Both routes are legal and clinically valid; they just apply different eligibility layers.

What a private prescriber looks at instead

Private prescribers, including those at GPhC-registered online pharmacies, work to the licensed indications and their own clinical governance standards. A reputable private consultation is not a formality. You will be asked about your medical history, your current medicines, your BMI, and any conditions that might affect suitability or safety. Identity is verified, and weight is confirmed, at nume, that includes a live video-based weight check, not a self-reported figure.

The Mounjaro doctor reviewing your case is a real clinician, not an automated system. Their job is to reach the same standard of decision a GP would reach, but working to the full licensed eligibility rather than the NHS's phased criteria. For most adults with a BMI above 30, or above 27 with a relevant health condition, there is a credible clinical basis for prescribing if nothing in the history rules it out. That said, approval is never guaranteed, suitability is always an individual clinical call.

For context on what the private market looks like and what a legitimate prescription includes, the guide to buying Mounjaro online safely covers the red flags to watch for and how to verify any pharmacy on the GPhC register. Worth reading before you commit to any provider.

How to move forward if you are not sure where you stand

If your GP has declined or you are not sure you meet NHS thresholds, the most useful next step is a structured private consultation. It costs nothing to find out whether you are clinically suitable, and the assessment will tell you clearly where you stand. There is no obligation to proceed.

When you are thinking about cost alongside clinical suitability, the weight-loss treatment overview sets out what is included at each stage of the process (consultation, prescription, aftercare) so there are no surprises. The specific question of NHS GP prescribing is covered in more detail if you want to understand the GP route before exploring private options.

NICE's appraisal of tirzepatide, TA1026, is the authoritative source on the clinical evidence underpinning the NHS access criteria, it is publicly available and explains what the committee concluded about the medicine's benefits and the populations most likely to benefit. Reading it alongside the NHS eligibility phases gives a clearer picture of why the phased rollout is structured as it is.

If a private consultation is the route that makes sense for your situation, start your free consultation with our prescribers and get a clear, clinical answer to whether Mounjaro is right for you.